Investors have boosted biotech startup Cerevance Inc.’s Series B financing to $65 million, powering its search for new approaches to battling neurological diseases. Cerevance, based in Boston, set out in January to raise $60 million. By late March, however, the company had elected to lock in the first $45 million, due to the upheaval caused by the coronavirus pandemic. In April, it held a first closing on that amount, Chief Executive Brad Margus said